AstraZeneca’s Lynparza (olaparib) + Bevacizumab Receive the US FDA’s Priority Review for 1L Treatment of Advanced Ovarian Cancers

 AstraZeneca’s Lynparza (olaparib) + Bevacizumab Receive the US FDA’s Priority Review for 1L Treatment of Advanced Ovarian Cancers

AstraZeneca’s Lynparza (olaparib) + Bevacizumab Receive the US FDA’s Priority Review for 1L Treatment of Advanced Ovarian Cancers

Shots:

  • The US FDA has accepted the sNDA and granted the PR for Lynparza in combination with bevacizumab as a maintenance therapy for patients with advanced ovarian cancer who are in complete or partial response to 1L platinum-based CT with bevacizumab
  • The PR is based on P-III PAOLA-1 study result assessing the combination therapy vs bevacizumab as monothx., demonstrating reduction in risk of diseases progression or death by 41% and an improvement in PFS (22.1 vs 16.6mos.), @2yrs. following trial initiation, no diseases progression (46% vs 28%)             
  • Lynparza (olaparib) is a first-in-class PARP inhibitor acts by targeting DNA damage response (DDR) in cells/tumors harboring a deficiency in HRR (BRCA1& 2 mutation) with its expected PDUFA date in Q2’20

Click here to­ read full press release/ article | Ref: AstraZeneca | Image: Twitter

Tuba Khan

Tuba Khan is Senior Editor at PharmaShots. She is curious, creative, and passionate about recent updates and innovation in the Life sciences industry. She covers Biopharma, MedTech, and Digital health segments. Tuba also has an experience of digital and social media marketing and runs the campaigns independently. She can be contacted on tuba@pharmashots.com

Related post